Posterior pituitary injection

Posterior pituitary injection has a strong contraction effect on smooth muscle, especially on blood vessels and the base of the uterus. Depending on the dosage, it can cause rhythmic contraction of the uterus to tonic contraction. It can also increase the tension of the intestines and bladder to cause them to contract. In addition, the posterior pituitary can also inhibit urination.

This product is a sterile solution prepared by dehydrating, drying, grinding the posterior pituitary gland of pigs, sheep, cattle and other animals and adding dilute acetic acid.

This product is a colorless, clear or almost clear liquid.

It is used for pulmonary and bronchial bleeding (such as hemoptysis) and digestive tract bleeding (hematemesis, blood in the stool), and is suitable for inducing labor in obstetrics, contracting the uterus and stopping bleeding after delivery. It is also effective for intestinal paralysis after abdominal surgery. This product also has the effect of reducing urine output in diabetes insipidus.

Intramuscular, subcutaneous injection or intravenous drip after dilution. Intravenous drip for induction or acceleration of labor: 1 2.5-5 units at a time, diluted with sodium chloride injection to contain 0.01 unit per 1 ml. At the beginning of intravenous drip, no more than 0.001-0.002 units per minute, increase by 0.001-0.002 units every 15-30 minutes until uterine contractions are similar to those during normal delivery, and the fastest is no more than 0.02 units per minute, usually 0.002-0.005 units per minute. 2 Control postpartum hemorrhage with intravenous drip of 0.02-0.04 units per minute, and 5-10 units can be injected intramuscularly after the placenta is expelled. Respiratory or digestive tract bleeding: 6-12 units at a time. Postpartum uterine bleeding: 3-6 units at a time.

After taking the medicine, if you experience pale complexion, sweating, palpitations, chest tightness, abdominal pain, anaphylactic shock, etc., you should stop taking the medicine immediately.

1. This product is not suitable for patients with nephritis, myocarditis, vascular sclerosis, narrow pelvis, twins, polyhydramnios, excessive uterine expansion, etc.; 2. It is not suitable for use when the cervix has not yet fully dilated; 3. It should be used with caution in patients with hypertension and coronary artery disease.

Precautions for children: This experiment has not been conducted and there is no reliable reference literature. Precautions for pregnancy and lactation: When used for inducing labor, the indication must be clear and the product must be used under close supervision. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference literature.

1. When cyclopropane and other hydrocarbons are inhaled for general anesthesia, the use of oxytocin can cause hypotension, sinus bradycardia or (and) atrioventricular dysrhythmia in the parturient. When enflurane concentration is >1.5% and halothane concentration is >1.0% during inhalation general anesthesia, the effect of the uterus on oxytocin is weakened. Enflurane concentration >3.0% can eliminate the reaction and may cause uterine bleeding. 2. When other uterotonic drugs are used simultaneously with oxytocin, the uterine tension may be too high, resulting in uterine rupture or (and) cervical tear.

Seal tightly, protect from light, and store in a cool place.

1ml: 6 units

24 months

Nanjing Xinbai Pharmaceutical Co., Ltd.

• Founded in:

  2001-03-28

• Address:

  No. 68, Xingang Avenue, Nanjing Economic and Technological Development Zone

• Tax NO.:

  91320192726088531G

• Registered Funds:

  147.85 million yuan

• Website:

  Log in to view

• Email:

  Log in to view